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Introduction {#sec005}
============

Bipolar disorder (BD) is a chronic psychiatric disease which can take most different and unpredictable courses. It is accompanied by unspecific brain structural changes and cognitive decline \[[@pone.0172699.ref001]--[@pone.0172699.ref006]\]. In the absence of reliable biomarkers, the diagnosis and evaluation of treatment success in BD is solely based upon clinical phenomenology and individual interpretation. Thus, the neurobiological underpinnings of BD are of particular interest and under permanent investigation.

Emerging evidence suggests that immune-inflammatory activity and tryptophan catabolites (TRYCATs) changes are involved in the etiology as well as in the course of BD. TRYCATs are proposed to be mediators of immune-inflammatory activity and also neurodegeneration \[[@pone.0172699.ref007]\]. Depression and mania are accompanied by the activation of immune inflammatory pathways like increased levels of pro-inflammatory cytokines which are connected to alterations in the TRYCAT metabolism \[[@pone.0172699.ref008]\].

Tryptophan is an essential amino acid and precursor for two critical biochemical pathways relevant to the inflammatory neuropsychiatric interface involving the generation of neurotransmitter 5- hydroxytryptamine (5-HT, serotonin) and the formation of kynurenine (KYN) and its derivatives \[[@pone.0172699.ref009]\].

First interpretations of these pathways involved that pro-inflammatory conditions lead to an induction of indoleamine 2,3-dioxygenase-1 (IDO-1) under which tryptophan is primarily converted into KYN leading to reduced availability of tryptophan for serotonin biosynthesis and, consequently, altered serotonergic transmission in the brain with neuropsychiatric symptoms as a direct result of this cascade \[[@pone.0172699.ref010], [@pone.0172699.ref011]\]. However, as the brain may be able to compensate for the inflammation-induced decrease in circulating tryptophan, the serotonergic system may not be affected unfavorably as part of this process \[[@pone.0172699.ref011]\].

Recent research suggests that TRYCATs may exert effects independently of serotonin \[[@pone.0172699.ref011]\]. While KYN itself is inactive, it is further converted into different metabolites. KYN can be converted into three different branches (see [Fig 1](#pone.0172699.g001){ref-type="fig"}).

1.  Due the enzymatic activity of kynurenine-3-monooxygenase (KMO), KYN is converted into 3-hydroxykynurenine (3-HK). Few enzymatic steps later in the cascade, 3-HK will be finally converted into quinolinic acid (QUIN). Both exert neurotoxic properties due to their ability to generate oxidative radicals and act as NMDA-receptor-agonists.

2.  Due the enzymatic activity of KYN aminotransferase II (KATII), KYN is converted into kynurenic acid (KYNA), which as a NMDA-receptor-antagonist (like the antidementive drug memantine) and α7-nicotinic acetylcholine receptor-antagonist tends to be neuroprotective \[[@pone.0172699.ref011], [@pone.0172699.ref012]\]. Kynurenic acid also acts neuroprotective against excitotoxicity of QUIN, but an abnormal accumulation of KYNA beyond physiological levels could induce glutamatergic hypo-functioning and might disturb cognitive function \[[@pone.0172699.ref013]\]. High KYNA levels are also discussed to be involved in the pathophysiology of cognitive and psychotic features of schizophrenia \[[@pone.0172699.ref014]\].

3.  KYN is a substrate for formation of anthranilic acid (AA), catalyzed by kynureninase (KYNU). Levels of AA were reported to be elevated in schizophrenia and the autoimmune diseases of rheumatoid arthritis and diabetes type 1 \[[@pone.0172699.ref015]--[@pone.0172699.ref017]\]. Less is reported about AA from a hypothetically relevant functional perspective. It might prevent tryptophan depletion, first by inhibiting sodium-transporters of uncharged solutes (e.g., tryptophan) across membranes \[[@pone.0172699.ref018]\], and second by serving as a substrate for bacteria metabolism, e.g. in the intestinal microbiome \[[@pone.0172699.ref019]\].

![Kynurenine pathway.\
Enzymes are written in italic.](pone.0172699.g001){#pone.0172699.g001}

To date, studies on TRYCAT alterations in BD have only sporadically been conducted. Elevated levels of KYN and KYNA have been described in the post mortem anterior cingulate in BD patients with a history of psychosis \[[@pone.0172699.ref020]\]. CSF studies showed higher KYNA levels in 31 male BD patients compared to 23 male healthy controls (HC) \[[@pone.0172699.ref021]\], and notably being associated to manic and psychotic features \[[@pone.0172699.ref022], [@pone.0172699.ref023]\]. Johannson et al. \[[@pone.0172699.ref024]\] showed TRYCAT-alterations in ten BD patients (two of them were euthymic) with increases of 3-HK and KYNA synthesis in cultures of skin fibroblasts compared to twelve HC \[[@pone.0172699.ref024]\].

In the current investigation, we wanted to elucidate the peripheral measurements of KYN metabolism in patients with BD. To our knowledge there is no study investigating blood levels and ratios of key components of the KYN pathway in a large BD compared to a large HC sample. In clinical studies, evaluation of ratios between end-products and substrates are used for the estimation of activities of enzymes \[[@pone.0172699.ref025]\].

We therefore analyzed the 3-HK/KYN as a proxy of the KMO, KYNA/KYN as a proxy of KAT II and AA/KYN as a proxy of KYNU. We also evaluated the 3-HK/KYNA ratio, as this ratio is often used in literature as a proxy of neurotoxic vs. neuroprotective end-product relation \[[@pone.0172699.ref026]\]. To complete the analysis we also wanted to present the serum levels of the pathway (KYN, KYNA, 3-HK and AA) and see if they differ between BD and HC.

Our hypothesis was that euthymic BD show a bias to the more neurotoxic cascade of KYN derivatives compared to HC. In particular this would imply a relative increase of the conversion of KYN to the neurotoxic 3-HK in the BD sample, presuming an accelerated KMO activity and additionally we expected an increased 3-HK/KYNA ratio.

Methods {#sec006}
=======

The study was conducted at the Medical University of Graz, Department of Psychiatry. All patients took part in the ongoing single centre BIPFAT study, that assesses demographic parameters, complete actual and lifetime psychiatric history using the Structured Clinical Interview according to DSM-IV (SCID I), the psychiatric rating scales Hamilton-Depression (HAM-D) \[[@pone.0172699.ref027]\], Young Mania Rating Scale (YMRS) \[[@pone.0172699.ref028]\] and Beck's Depression Inventory (BDI) \[[@pone.0172699.ref029]\], history of medication, anthropometric measure, blood pressure, fasting blood, cognitive testing, EEG, stool sample, different lifestyle questionnaires and magnetic resonance imaging (MRI) of the brain. All patients included were former in- or outpatients of the Medical University of Graz and had a diagnosis of BD I or BD II according to the DSM-IV criteria. Patients needed to be in the state of euthymia or mild depression (HAM-D score \<14 and YMRS \<9) and had given written informed consent prior to participating in the study.

The study has been approved by the local ethics committee (Medical University of Graz, Austria) in compliance with the current revision of the Declaration of Helsinki, ICH guideline for Good Clinical Practice and current regulations (EK-number: 24--123 ex 11/12).

Exclusion criteria were the presence of chronic obstructive pulmonary disease, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, neurodegenerative and neuroinflammatory disorders (i.e. Alzheimer\'s, Huntington\'s and Parkinson\'s disorder, multiple sclerosis), hemodialysis and interferon-α-based immunotherapy. Further exclusion criteria for controls were the presence of lifetime psychiatric diagnoses (verified by SCID I) and first and second grade relationship to relatives with psychiatric disorders. For further information about the study design and preliminary results see our previous reports \[[@pone.0172699.ref002], [@pone.0172699.ref030]--[@pone.0172699.ref033]\].

We took peripheral TRYCAT blood levels of 143 euthymic and mild depressive BD patients and 101 healthy controls. Targeted parameters were the levels of KYN, KYNA, 3-HK and AA, the ratio between end-products and substrates as proxies for the specific enzymatic activity (3-HK/KYN, KYNA/KYN, AA/KYN) as well as 3-HK/KYNA as a proxy for neurotoxic vs. neuroprotective end-product relation. Because of technical issues AA could only be evaluated in 113 BD and 88 HC.

For statistical analysis two multivariate analyses of covariance (MANCOVA) separated for targeted parameters involving AA (113 BD and 88 HC)and not involving AA (BD:143 and HC:101) controlled for age, sex, body mass index, presence of a cardiovascular disease and smoking were performed, as the groups differed in these parameters (see [Table 1](#pone.0172699.t001){ref-type="table"}).

10.1371/journal.pone.0172699.t001

###### Demographic and clinical parameters.

![](pone.0172699.t001){#pone.0172699.t001g}

                                                                        BD (n = 143)   HC (n = 101)   *Statistics*           *p*
  --------------------------------------------------------------------- -------------- -------------- ---------------------- ------------
  **Male (%)**[\*](#t001fn002){ref-type="table-fn"}                     55.9           39.6           ***χ 2 = 6*.*323***    **.*012***
  **Age (years) (M, SD)**[\*](#t001fn002){ref-type="table-fn"}          43.9 (13.3)    40.3 (16.4)    ***U = -2*.*392***     **.*017***
  **Body Mass Index (M, SD)**[\*\*](#t001fn003){ref-type="table-fn"}    28.2 (6.2)     24.7 (4.3)     ***U = -4*.*954***     **.*000***
  **Cardiovascular Disease (%)**[\*](#t001fn002){ref-type="table-fn"}   29.4           26.8           ***χ 2 = 5*.*035***    **.*025***
  **Smoking (%)**[\*\*](#t001fn003){ref-type="table-fn"}                48.3           26.7           ***χ 2 = 10*.*502***   **.*001***
  **Lithium (%)**                                                       32.2           0              ***n*.*a*.**           
  **Antipsychotics (%)**                                                62.2           0              ***n*.*a*.**           
  **Antiepileptics (%)**                                                32.2           0              ***n*.*a*.**           
  **Two or more mood stabilizer (%)**                                   33.6           0              ***n*.*a*.**           
  **Antidepressant (%)**                                                68.5           0              ***n*.*a*.**           
  **Bipolar Disorder I (%)**                                            61.5           ***n*.*a*.**   ***n*.*a*.**           
  **Bipolar Disorder II (%)**                                           35.0           ***n*.*a*.**   ***n*.*a*.**           

Note: Results from Chi square tests (*χ2*) and Mann-Whitney-U-tests (*U*). Statistically significant effects are marked bold. (n.a. = not applicable)

\*p \<.05,

\*\* \<.01

We didn't control for medication because every BD patient had at least one kind of psychopharmacologic medication while HC didn't. Thus it was simply not a feature applying to both groups and not suitable as a factor to control for. Moreover to address this point we analyzed if the targeted parameters differed in between patients with different kind of medications (lithium, antipsychotics, antiepileptics and antidepressants), which was not the case (data not shown).

Biological assays/Quantification of KYN pathway metabolites (TRYCATs) {#sec007}
---------------------------------------------------------------------

The chromatographic system was composed of a Waters Acquity UPLC separations module connected to a Xevo TQ MS triple-quadrupole mass spectrometer, equipped with a Z-spray ESI ion source (Waters Corp., Milford, MA, USA). Separation was carried out using a Kinetex XB-C18, 2.6 μm, 2.1 x 150 mm column (Phenomenex, Torrance, CA, USA).

Reagents for protein precipitation, derivatization, and chromatography were purchased from Sigma-Aldrich (St. Louis, MO, USA) and Biosolve (Valkenswaard, NL).

KYN, AA, 3-HK and KYNA, were purchased from Sigma-Aldrich. The internal standard KYNA-D5 was purchased from CDN Isotopes (Pointe-Claire, QC, Canada), KYN-D4 was purchased from Buchem BV (Minden, NL). Standards and a low and high quality control were established by adding defined amounts of each analyte to human serum samples (obtained from a blood bank). The human serum was necessary to take matrix effects into account, in order to cover concentrations below the analyte concentrations present in healthy humans the serum was diluted 1+1 with LC-MS/MS grade water and used as the lowest calibrator. The values of this calibrator were calculated by standard addition. As serum without these analytes is not available as there is no blank sample. A total volume of 300 μl serum samples, calibrators and controls was used for sample preparation. Analytes were extracted by adding 50 μl of 2.0 M urea and 50 μl of an internal standard solution containing KYN-D4 and KYNA-D5. Two precipitation steps by subsequently adding 200 μl methanol/ethanol (2/1 v:v) and 800 μl acetonitrile were carried out. The supernatant was separated into two portions, which were evaporated separately. One of these portions was directly reconstituted in mobile phase, while the other portion was derivatised with 200 μl HCl/Butanol at 90°C for 60 minutes. After evaporation this portion was reconstituted in mobile phase as well.

For chromatography, 7.5 μl of the reconstituted samples, calibrators and controls were loaded onto the LC-MS/MS system. The analytes were analysed in the underivatised sample. Gradient methods with a total duration of 7.5 min each were used for chromatographic separation. Mobile phase A was composed of 0.1% formic acid and 0.01% HFBA in water, mobile phase B was methanol. Flow rate was set at 0.25 ml/min, column temperature was set at 30.0°C. Retention times for the analytes were between 3.1 and 6.0 min.

The Xevo TQ MS was operating in atmospheric pressure and electrospray ionization in positive mode (ESI+). Ion source settings were: capillary voltage, 1.00 kV; desolvation temperature 650°C; source temperature, 150°C; nitrogen was used as desolvation gas with an API gas flow rate of 1200 l/h; argon was used as collision gas at a flow rate of 0.15 ml/min. The analytes and internal standards were detected using multi reaction monitoring (MRM) technique. System operation, data acquisition and data processing were controlled using MassLynx V4.1 software (Waters Corp.). The Lower Limit of Quantification and Lower Limit of Detection of the used method were calculated according to DIN 32645 guidelines. The method was further validated based on the EMEA guidelines at the Institute of Laboratory Medicine, Medical Center of Ludwig Maximilian University, Munich, Germany.

Results {#sec008}
=======

The levels of KYNA (*F = 5*,*579; p \<*.*05*) were reduced in BD compared to HC (see Figs [2](#pone.0172699.g002){ref-type="fig"} and [3](#pone.0172699.g003){ref-type="fig"}). There was no statistical difference in the other parameters.

![Serum levels of TRYCATs in ng/mL.\
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![Scatter graphs showing the distribution of the serum levels of the measured TRYCATs in ng/mL.](pone.0172699.g003){#pone.0172699.g003}

The approximated enzymatic activity of the kynurenine-3-monooxygenase (KMO) reflected by the 3-HK/KYN ratio was increased in BD individuals compared to HC (*F = 5*,*394; p \<*.*05*). Additionally the ratio of 3-HK/KYNA was increased in individuals with BD compared to HC (*F = 11*,*357; p \<*.*01*) (see Figs [4](#pone.0172699.g004){ref-type="fig"} and [5](#pone.0172699.g005){ref-type="fig"}). There was no statistical difference in the other investigated ratios.

![Ratios of TRYCAT metabolism.\
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![Scatter graphs showing the distributions of the TRYCAT metabolism ratios.](pone.0172699.g005){#pone.0172699.g005}

Chromatograms of the investigated tryptophan pathway intermediates analyzed with high pressure liquid chromatography coupled with mass spectrometry (HPLC-MS/MS) in Multiple Reaction Monitoring (MRM) are shown in the supplementary [S1 File](#pone.0172699.s001){ref-type="supplementary-material"}.

Discussion {#sec009}
==========

The aim of the present study was to elucidate the KYN pathway in euthymic individuals with BD. We wanted to evaluate the serum levels of KYN, KYNA, 3-HK and AA as well as the approximated activity of the KMO (measured by 3-HK/KYN ratio), KAT II (measured by KYNA/KYN ratio), KYNU (measured by AA/KYN ratio) and the relation of the neurotoxic TRYCAT 3-HK compared to the more neuroprotective TRYCAT KYNA (measured by 3-HK/KYNA ratio) between euthymic individuals with BD and HC.

The results presented here give further supporting evidence for the contribution of TRYCATs, in particular KYN and its derivatives, to the pathophysiology of BD.

We could show a significant bias to the neurotoxic branch of KYN breakdown. The level of KYNA was significantly decreased in individuals with BD, while the increase in 3-HK levels compared to HCs didn't reach statistical significance. There was a significant increase of 3-HK compared to the more neuroprotective KYNA, evident by an increased 3-HK/KYNA ratio, as well as an increased 3-HK/KYN ratio, as a proxy for KMO activity, in a sample of 143 euthymic BD patients compared to 101 HC. There was no significant difference of the approximated KAT II or KYNU activity between BD and HC.

TRYCATs are proposed to be mediators of immune-inflammatory activity and also neurodegeneration \[[@pone.0172699.ref007]\]. This increase of the neurotoxic catabolite 3-HK compared to the neuroprotective KYNA even in the state of euthymia might relate to cognitive dysfunction, which is prevalent in acute phases of BD, but also frequently prevails in euthymia \[[@pone.0172699.ref001], [@pone.0172699.ref002]\]. These processes might also be partially responsible for unspecific brain structural changes in BD, like reduction in grey and white matter, increased white matter lesions and microstructural changes which can be found in various Magnetic resonance imaging (MRI)-studies \[[@pone.0172699.ref003]--[@pone.0172699.ref006]\]. Alterations in different immune-inflammatory processes are evident in BD. In particular its implications to the KYN pathway have been highlighted by the study of Johansson et al. \[[@pone.0172699.ref024]\], which showed that pro-inflammatory cytokine treatment (with human recombinants of interleukin-1, interleukin-6, tumor-necrosis-factor and interferon-α (IFN-α) led to an IDO-1 activation and further increase of the already elevated 3-HK/KYNA ratio, in cultures of skin fibroblasts, suggesting that pro-inflammatory states are linked to an even greater imbalance. Raisson et al. \[[@pone.0172699.ref034]\] showed a significant increase towards the KYN-pathway metabolism combined with associated increase of depressive symptoms in 27 hepatitis C following a IFN-α treatment. The IDO-1 activity in general is enhanced by inflammatory pathways. We could show this in our previous preliminary results on increased IDO-1 activity in euthymic BD patients compared to HC with greater increases noted in the subsample of overweight BD patients \[[@pone.0172699.ref030]\]. However, the tryptophan breakdown in peripheral blood of individuals with BD has not been extensively studied to date.

Accumulating evidence suggests that mild inflammatory processes in the periphery and the brain are involved in the pathophysiology of BD across manic and depressive episodes but may prevail throughout the euthymic "between-episode" period as a chronic process \[[@pone.0172699.ref035], [@pone.0172699.ref036]\]. The euthymia in BD is of special interest, as it is characterized by the absence of affective symptoms and the confounding of a state effect is removed. We also controlled for the potential confounding factors obesity, smoking and cardiovascular disease, as they are all linked to low grade inflammation \[[@pone.0172699.ref037]--[@pone.0172699.ref039]\] and were significantly more common in the investigated BD group in our cohort, as expected due different earlier studies \[[@pone.0172699.ref040]--[@pone.0172699.ref042]\].

As a result of these foregoing observations it seems like we could at least hypothetically think about crafting an approach to a possible biomarker (or at least a part of a combined biomarker with other parameters) for the recognition and staging of disease episodes in BD. As manic and depressive episodes seem to be accompanied by increased inflammation \[[@pone.0172699.ref035], [@pone.0172699.ref036]\], a measureable individual activation of the KYN-pathway could be detectable. To further elucidate that process a longitudinal assessment-approach across episodes in individuals with BD seems like a good way to achieve that information.

Limitations {#sec010}
-----------

The mismatch of BD patients and healthy controls in important parameters, even if we controlled for their influence, especially the difference in age is a limiting factor of the study. The medication might also be of limiting contribution, as all BD individuals had psychopharmacological treatment, while no HC had these kinds of medications. To address this point we analyzed if the targeted parameters differed in between patients with different kind of medications. Despite this was not the case in our sample, the influence of ongoing drug treatment among patients can still not be ruled out. The study is also limited by its cross-sectional design. The contribution of neurotoxic TRYCATs to cognitive decline and brain structural abnormalities despite being logically sound is only hypothetical. Another limitation comes from the fact that we took peripheral levels of the targeted parameters. This could be a problem for the interpretation of KYNA levels and ratios as animal models teach us that KYNA diffuse only in very low rate beyond the brain-blood barrier \[[@pone.0172699.ref043]\]. However, other authors propose that the same processes involving KYN catabolism in the brain should basically also take place in the periphery \[[@pone.0172699.ref008], [@pone.0172699.ref034]\]. The other TRYCATS (KYN, 3-HK and AA) are proposed to pass the brain-blood barrier easily \[[@pone.0172699.ref043], [@pone.0172699.ref044]\]. Nevertheless, as we are unable to precisely relate the peripheral measurement of the investigated metabolites to the central nervous system in general and especially not to the relevant brain regions or circuits, it seems far too speculative to say these markers should be seen in a causative role for the disorder itself. In this context, we have to point out that the investigated plasma metabolites should rather be seen as surrogate markers.

A further limitation is the use of the 3-HK/KYN ratio as a proxy of the KMO activity as it may also reflect increased availability of precursor, i.e. kynurenine, especially in the view of decreased conversion of KYN to KYNA. Considering the fact that the enzyme does not operate under full saturation, bigger pool of KYN will be also be converted into 3-HK without noticeable changes in free KYN levels.

Conclusion and future directions {#sec011}
--------------------------------

In conclusion our findings subserve the concept of KYN-pathway alterations in the pathophysiology of BD. We present evidence of increased breakdown towards the neurotoxic branch in KYN metabolism, which could be involved in the development of brain structural changes and cognitive deficits in BD although direct extrapolation from observations made in serum to brain cell metabolism remains elusive. Further research should focus on state dependent changes in TRYCATs and its relation to cognition, brain structure and staging parameters favorably in a longitudinal design across different episodes of disease. Moreover, the contribution of sex and metabolic parameters seems to be of special interest and should be further analyzed.

Supporting information {#sec012}
======================

###### Chromatograms of tryptophan pathway intermediates.

Chromatograms of the investigated tryptophan pathway intermediates analyzed with high pressure liquid chromatography coupled with mass spectrometry (HPLC-MS/MS) in Multiple Reaction Monitoring (MRM).

(PDF)
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Click here for additional data file.
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